Register a trial

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05572515




Registration number
NCT05572515
Ethics application status
Date submitted
5/10/2022
Date registered
7/10/2022

Titles & IDs
Public title
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
Scientific title
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide
Secondary ID [1] 0 0
64007957MMY3006
Secondary ID [2] 0 0
CR109244
Universal Trial Number (UTN)
Trial acronym
MajesTEC-9
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Relapsed or Refractory Multiple Myeloma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Other cancer types

Intervention/exposure
Study type
Interventional(has expanded access)
Description of intervention(s) / exposure
Treatment: Drugs - Teclistamab
Treatment: Drugs - Pomalidomide
Treatment: Drugs - Bortezomib
Treatment: Drugs - Dexamethasone
Treatment: Drugs - Carfilzomib

Experimental: Teclistamab - Participants will receive teclistamab monotherapy in Part 1 and an alternative dosing regimen of teclistamab in Part 2.

Experimental: Pomalidomide, Bortezomib and Dexamethasone (PVd) or Carfilzomib and Dexamethasone (Kd) - Participants will receive either PVd or Kd based on principal investigator's choice during Part 1 of the study.


Treatment: Drugs: Teclistamab
Teclistamab will be administered subcutaneously.

Treatment: Drugs: Pomalidomide
Pomalidomide will be administered orally.

Treatment: Drugs: Bortezomib
Bortezomib will be administered subcutaneously.

Treatment: Drugs: Dexamethasone
Dexamethasone will be administered orally in PVd and intravenously or orally in Kd.

Treatment: Drugs: Carfilzomib
Carfilzomib will be administered intravenously.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Part 1: Progression-free Survival (PFS)
Timepoint [1] 0 0
Up to 9 years
Primary outcome [2] 0 0
Part 2: Number of Participants Reporting Cytokine Release Syndrome (CRS) Cases by Severity
Timepoint [2] 0 0
Up to 9 years
Secondary outcome [1] 0 0
Part 1 and 2: Overall Response (Partial Response [PR] or Better)
Timepoint [1] 0 0
Up to 9 years
Secondary outcome [2] 0 0
Part 1 and 2: Very Good Partial Response (VGPR) or Better Response
Timepoint [2] 0 0
Up to 9 years
Secondary outcome [3] 0 0
Part 1 and 2: Complete Response (CR) or Better Response
Timepoint [3] 0 0
Up to 9 years
Secondary outcome [4] 0 0
Part 1: Duration of Response (DOR)
Timepoint [4] 0 0
Up to 9 years
Secondary outcome [5] 0 0
Part 1: Time to Next Treatment (TTNT)
Timepoint [5] 0 0
Up to 9 years
Secondary outcome [6] 0 0
Part 1: Progression-free Survival on Next-line Therapy (PFS2)
Timepoint [6] 0 0
Up to 9 years
Secondary outcome [7] 0 0
Part 1: Overall Survival (OS)
Timepoint [7] 0 0
Up to 9 years
Secondary outcome [8] 0 0
Part 1 and 2: Number of Participants with Adverse Events (AEs) by Severity
Timepoint [8] 0 0
Up to 9 years
Secondary outcome [9] 0 0
Part 1 and 2: Number of Participants with Serious Adverse Events (SAEs) by Severity
Timepoint [9] 0 0
Up to 9 years
Secondary outcome [10] 0 0
Part 1 and 2: Number of Participants with Abnormal Laboratory Results
Timepoint [10] 0 0
Up to 9 years
Secondary outcome [11] 0 0
Part 1 and 2: Serum Concentrations of Teclistamab
Timepoint [11] 0 0
Up to 9 years
Secondary outcome [12] 0 0
Part 1 and 2: Number of Participants with Anti-drug Antibodies (ADAs) to Teclistamab
Timepoint [12] 0 0
Up to 9 years
Secondary outcome [13] 0 0
Part 1: Change from Baseline in Symptoms, Functioning, and Overall Health-related Quality of Life (HRQoL) as Assessed by European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC-QLQ-C30)
Timepoint [13] 0 0
Baseline up to 9 years
Secondary outcome [14] 0 0
Part 1: Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) Scale Score
Timepoint [14] 0 0
Baseline up to 9 years
Secondary outcome [15] 0 0
Part 1: Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Timepoint [15] 0 0
Baseline up to 9 years
Secondary outcome [16] 0 0
Part 1: Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by EuroQol Five Dimension Questionnaire 5-Level (EQ-5D-5L)
Timepoint [16] 0 0
Baseline up to 9 years
Secondary outcome [17] 0 0
Part 1: Time to Worsening in Symptoms, Functioning, and Overall HRQoL
Timepoint [17] 0 0
Up to 9 years
Secondary outcome [18] 0 0
Part 1: PFS in Participants in High-risk Molecular Features
Timepoint [18] 0 0
Up to 9 years
Secondary outcome [19] 0 0
Part 1: Depth of Response in Participants in High-risk Molecular Features
Timepoint [19] 0 0
Up to 9 years

Eligibility
Key inclusion criteria
* Documented diagnosis of multiple myeloma as defined by the criteria below: (a)Multiple myeloma diagnosis according to International Myeloma Working Group (IMWG) diagnostic criteria (b) Measurable disease at screening as defined by any of the following: (1) Serum M-protein level greater than or equal to (>=)0.5 grams per deciliter (g/dL) (central laboratory); or (2) Urine M-protein level >=200 milligrams (mg)/24 hours (central laboratory); or (3) Serum immunoglobulin free light chain >=10 milligrams per deciliter (mg/dL) (central laboratory) and abnormal serum immunoglobulin kappa lambda free light chain ratio
* Received 1 to 3 prior lines of antimyeloma therapy including a minimum of 2 consecutive cycles of an anti- cluster of differentiation 38 (CD38) monoclonal antibody at the approved dosing regimen in any prior line and 2 consecutive cycles of lenalidomide in any prior line
* Documented evidence of progressive disease or failure to achieve a response to last line of therapy based on investigator's determination of response by International myeloma working group (IMWG) criteria
* Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2
* A female participant must agree not to be pregnant, breast-feeding, or plan to become pregnant while enrolled in this study or within 6 months after the last dose of study treatment
* Must be willing and able to adhere to the lifestyle restrictions specified in this protocol
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Received any prior B cell maturation antigen (BCMA)-directed therapy
* A participant is not eligible to receive PVd as control therapy if any of the following are present: (1) Received prior pomalidomide therapy, (2) Does not meet criteria for bortezomib retreatment (3) Contraindications or life-threatening allergies, hypersensitivity, or intolerance to pomalidomide or bortezomib, (4) Grade 1 peripheral neuropathy with pain or Grade greater than or equal to (>=) 2 peripheral neuropathy as defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0, (5) Received a strong cytochrome P (CYP) 3A4 inducer within 5 half-lives prior to randomization; A participant is not eligible to receive Kd as control therapy if any of the following are present:(1) Received prior carfilzomib therapy, (2) Uncontrolled hypertension, defined as an average systolic blood pressure greater than (>)159 millimeters of mercury (mmHg) or diastolic blood pressure >99 mmHg despite optimal treatment (3) Grade 2 peripheral neuropathy with pain or Grade >=3 peripheral neuropathy as defined by NCI-CTCAE Version 5.0, (4) Contraindications or life-threatening allergies, hypersensitivity, or intolerance to carfilzomib (intolerance defined as prior therapy discontinued due to any adverse event [AE] related to carfilzomib)
* Received a maximum cumulative dose of corticosteroids of >=140 mg of prednisone or equivalent within 14 days prior to randomization
* Received a live, attenuated vaccine within 4 weeks before randomization
* Central nervous system (CNS) involvement or clinical signs of meningeal involvement of multiple myeloma
* Plasma cell leukemia at the time of screening, Waldenstrom's macroglobulinemia, polyneuropathy, organomegaly, endocrinopathy, M-protein (POEMS) syndrome and skin changes, or primary amyloid light chain amyloidosis

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
29/03/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
31/08/2031
Actual
Sample size
Target
650
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Blacktown Hospital - Blacktown
Recruitment hospital [2] 0 0
St Vincents Hospital Melbourne - Fitzroy
Recruitment hospital [3] 0 0
Box Hill Hospital - Melbourne
Recruitment hospital [4] 0 0
Fiona Stanley Hospital - Murdoch
Recruitment hospital [5] 0 0
Sir Charles Gairdner Hospital - Nedlands
Recruitment postcode(s) [1] 0 0
2148 - Blacktown
Recruitment postcode(s) [2] 0 0
3065 - Fitzroy
Recruitment postcode(s) [3] 0 0
3128 - Melbourne
Recruitment postcode(s) [4] 0 0
6150 - Murdoch
Recruitment postcode(s) [5] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alaska
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Iowa
Country [7] 0 0
United States of America
State/province [7] 0 0
Louisiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Maryland
Country [9] 0 0
United States of America
State/province [9] 0 0
Massachusetts
Country [10] 0 0
United States of America
State/province [10] 0 0
Missouri
Country [11] 0 0
United States of America
State/province [11] 0 0
New Jersey
Country [12] 0 0
United States of America
State/province [12] 0 0
New York
Country [13] 0 0
United States of America
State/province [13] 0 0
North Carolina
Country [14] 0 0
United States of America
State/province [14] 0 0
Pennsylvania
Country [15] 0 0
United States of America
State/province [15] 0 0
Texas
Country [16] 0 0
United States of America
State/province [16] 0 0
Utah
Country [17] 0 0
United States of America
State/province [17] 0 0
Virginia
Country [18] 0 0
United States of America
State/province [18] 0 0
Washington
Country [19] 0 0
Austria
State/province [19] 0 0
Salzburg
Country [20] 0 0
Austria
State/province [20] 0 0
Vienna
Country [21] 0 0
Belgium
State/province [21] 0 0
Brasschaat
Country [22] 0 0
Belgium
State/province [22] 0 0
Haine-St-Paul
Country [23] 0 0
Belgium
State/province [23] 0 0
Kortrijk
Country [24] 0 0
Belgium
State/province [24] 0 0
Leuven
Country [25] 0 0
Belgium
State/province [25] 0 0
Liege
Country [26] 0 0
Brazil
State/province [26] 0 0
Brasilia
Country [27] 0 0
Brazil
State/province [27] 0 0
Caxias do Sul
Country [28] 0 0
Brazil
State/province [28] 0 0
Curitiba
Country [29] 0 0
Brazil
State/province [29] 0 0
Joinville
Country [30] 0 0
Brazil
State/province [30] 0 0
Natal
Country [31] 0 0
Brazil
State/province [31] 0 0
Niteroi
Country [32] 0 0
Brazil
State/province [32] 0 0
Rio de Janeiro
Country [33] 0 0
Brazil
State/province [33] 0 0
Salvador
Country [34] 0 0
Brazil
State/province [34] 0 0
Sao Jose do Rio Preto
Country [35] 0 0
Brazil
State/province [35] 0 0
Sao Paulo
Country [36] 0 0
Brazil
State/province [36] 0 0
São Paulo
Country [37] 0 0
Canada
State/province [37] 0 0
Alberta
Country [38] 0 0
Canada
State/province [38] 0 0
New Brunswick
Country [39] 0 0
Canada
State/province [39] 0 0
Ontario
Country [40] 0 0
Canada
State/province [40] 0 0
Quebec
Country [41] 0 0
China
State/province [41] 0 0
Beijing
Country [42] 0 0
China
State/province [42] 0 0
Changchun
Country [43] 0 0
China
State/province [43] 0 0
Changsha
Country [44] 0 0
China
State/province [44] 0 0
Chengdu
Country [45] 0 0
China
State/province [45] 0 0
Chongqing
Country [46] 0 0
China
State/province [46] 0 0
Fu Zhou
Country [47] 0 0
China
State/province [47] 0 0
Guangzhou
Country [48] 0 0
China
State/province [48] 0 0
Hangzhou
Country [49] 0 0
China
State/province [49] 0 0
Harbin
Country [50] 0 0
China
State/province [50] 0 0
Nanchang
Country [51] 0 0
China
State/province [51] 0 0
Nanjing
Country [52] 0 0
China
State/province [52] 0 0
Nanning
Country [53] 0 0
China
State/province [53] 0 0
Shanghai
Country [54] 0 0
China
State/province [54] 0 0
Shenyang
Country [55] 0 0
China
State/province [55] 0 0
Shenzhen
Country [56] 0 0
China
State/province [56] 0 0
Tian Jin
Country [57] 0 0
China
State/province [57] 0 0
Tianjin
Country [58] 0 0
China
State/province [58] 0 0
Wenzhou
Country [59] 0 0
China
State/province [59] 0 0
Wuhan
Country [60] 0 0
China
State/province [60] 0 0
Wuxi
Country [61] 0 0
China
State/province [61] 0 0
Xi'an
Country [62] 0 0
China
State/province [62] 0 0
Zhengzhou
Country [63] 0 0
Czechia
State/province [63] 0 0
Brno
Country [64] 0 0
Czechia
State/province [64] 0 0
Olomouc
Country [65] 0 0
Czechia
State/province [65] 0 0
Ostrava - Poruba
Country [66] 0 0
Czechia
State/province [66] 0 0
Praha 2
Country [67] 0 0
Denmark
State/province [67] 0 0
Aalborg
Country [68] 0 0
Denmark
State/province [68] 0 0
Aarhus
Country [69] 0 0
Denmark
State/province [69] 0 0
Copenhagen
Country [70] 0 0
Denmark
State/province [70] 0 0
Herning
Country [71] 0 0
Denmark
State/province [71] 0 0
Odense C
Country [72] 0 0
Denmark
State/province [72] 0 0
Vejle
Country [73] 0 0
France
State/province [73] 0 0
AMIENS cedex 1
Country [74] 0 0
France
State/province [74] 0 0
Caen cedex 9
Country [75] 0 0
France
State/province [75] 0 0
Grenoble
Country [76] 0 0
France
State/province [76] 0 0
Le Mans
Country [77] 0 0
France
State/province [77] 0 0
Lille
Country [78] 0 0
France
State/province [78] 0 0
Montpellier
Country [79] 0 0
France
State/province [79] 0 0
Nantes Cedex 1
Country [80] 0 0
France
State/province [80] 0 0
Paris
Country [81] 0 0
France
State/province [81] 0 0
Toulouse
Country [82] 0 0
France
State/province [82] 0 0
Vandœuvre-lès-Nancy
Country [83] 0 0
Germany
State/province [83] 0 0
Cottbus
Country [84] 0 0
Germany
State/province [84] 0 0
Dresden
Country [85] 0 0
Germany
State/province [85] 0 0
Greifswald
Country [86] 0 0
Germany
State/province [86] 0 0
Hamburg
Country [87] 0 0
Germany
State/province [87] 0 0
Heidelberg
Country [88] 0 0
Germany
State/province [88] 0 0
Marburg
Country [89] 0 0
Germany
State/province [89] 0 0
Tübingen
Country [90] 0 0
Germany
State/province [90] 0 0
Ulm
Country [91] 0 0
Germany
State/province [91] 0 0
Zwickau
Country [92] 0 0
Greece
State/province [92] 0 0
Athens Attica
Country [93] 0 0
Greece
State/province [93] 0 0
Patra
Country [94] 0 0
Greece
State/province [94] 0 0
Thessaloniki
Country [95] 0 0
India
State/province [95] 0 0
Gurgaon
Country [96] 0 0
India
State/province [96] 0 0
Jaipur
Country [97] 0 0
India
State/province [97] 0 0
Pune
Country [98] 0 0
Israel
State/province [98] 0 0
Hadera
Country [99] 0 0
Israel
State/province [99] 0 0
Haifa
Country [100] 0 0
Israel
State/province [100] 0 0
Petah Tikva
Country [101] 0 0
Israel
State/province [101] 0 0
Ramat Gan
Country [102] 0 0
Israel
State/province [102] 0 0
Tel-Aviv
Country [103] 0 0
Italy
State/province [103] 0 0
Bologna
Country [104] 0 0
Italy
State/province [104] 0 0
Milano
Country [105] 0 0
Italy
State/province [105] 0 0
Palermo
Country [106] 0 0
Italy
State/province [106] 0 0
Pisa
Country [107] 0 0
Italy
State/province [107] 0 0
Reggio Emilia
Country [108] 0 0
Italy
State/province [108] 0 0
Roma
Country [109] 0 0
Italy
State/province [109] 0 0
Siena
Country [110] 0 0
Italy
State/province [110] 0 0
Turin
Country [111] 0 0
Italy
State/province [111] 0 0
Udine
Country [112] 0 0
Italy
State/province [112] 0 0
Varese
Country [113] 0 0
Japan
State/province [113] 0 0
Bunkyo ku
Country [114] 0 0
Japan
State/province [114] 0 0
Chiba
Country [115] 0 0
Japan
State/province [115] 0 0
Gifu
Country [116] 0 0
Japan
State/province [116] 0 0
Gunma
Country [117] 0 0
Japan
State/province [117] 0 0
Hirakata
Country [118] 0 0
Japan
State/province [118] 0 0
Hitachi
Country [119] 0 0
Japan
State/province [119] 0 0
Iruma-gun
Country [120] 0 0
Japan
State/province [120] 0 0
Kamogawa City
Country [121] 0 0
Japan
State/province [121] 0 0
Kashiwa
Country [122] 0 0
Japan
State/province [122] 0 0
Kurashiki
Country [123] 0 0
Japan
State/province [123] 0 0
Matsuyama
Country [124] 0 0
Japan
State/province [124] 0 0
Nagakute
Country [125] 0 0
Japan
State/province [125] 0 0
Nagasaki-Shi
Country [126] 0 0
Japan
State/province [126] 0 0
Niigata
Country [127] 0 0
Japan
State/province [127] 0 0
Okayama
Country [128] 0 0
Japan
State/province [128] 0 0
Osaka
Country [129] 0 0
Japan
State/province [129] 0 0
Sapporo
Country [130] 0 0
Japan
State/province [130] 0 0
Tokyo
Country [131] 0 0
Japan
State/province [131] 0 0
Yamagata
Country [132] 0 0
Japan
State/province [132] 0 0
Yamanashi
Country [133] 0 0
Malaysia
State/province [133] 0 0
Georgetown
Country [134] 0 0
Malaysia
State/province [134] 0 0
Kota Kinabalu
Country [135] 0 0
Malaysia
State/province [135] 0 0
Kuala Lumpur
Country [136] 0 0
Malaysia
State/province [136] 0 0
Subang Jaya
Country [137] 0 0
Netherlands
State/province [137] 0 0
Amersfoort
Country [138] 0 0
Netherlands
State/province [138] 0 0
Amsterdam
Country [139] 0 0
Netherlands
State/province [139] 0 0
Groningen
Country [140] 0 0
Netherlands
State/province [140] 0 0
Utrecht
Country [141] 0 0
Poland
State/province [141] 0 0
Gdansk
Country [142] 0 0
Poland
State/province [142] 0 0
Katowice
Country [143] 0 0
Poland
State/province [143] 0 0
Kielce
Country [144] 0 0
Poland
State/province [144] 0 0
Lublin
Country [145] 0 0
Portugal
State/province [145] 0 0
Almada
Country [146] 0 0
Portugal
State/province [146] 0 0
Braga
Country [147] 0 0
Portugal
State/province [147] 0 0
Lisbon
Country [148] 0 0
Portugal
State/province [148] 0 0
Porto
Country [149] 0 0
Portugal
State/province [149] 0 0
Vila Nova de Gaia
Country [150] 0 0
Spain
State/province [150] 0 0
Badalona
Country [151] 0 0
Spain
State/province [151] 0 0
Hospitalet de Llobregat
Country [152] 0 0
Spain
State/province [152] 0 0
Jerez de la Frontera
Country [153] 0 0
Spain
State/province [153] 0 0
Leon
Country [154] 0 0
Spain
State/province [154] 0 0
Madrid
Country [155] 0 0
Spain
State/province [155] 0 0
Murcia
Country [156] 0 0
Spain
State/province [156] 0 0
Oviedo
Country [157] 0 0
Spain
State/province [157] 0 0
Palma de Mallorca
Country [158] 0 0
Spain
State/province [158] 0 0
Pontevedra
Country [159] 0 0
Spain
State/province [159] 0 0
Pozuelo de Alarcon
Country [160] 0 0
Spain
State/province [160] 0 0
València
Country [161] 0 0
Sweden
State/province [161] 0 0
Falun
Country [162] 0 0
Sweden
State/province [162] 0 0
Helsingborg
Country [163] 0 0
Sweden
State/province [163] 0 0
Uppsala
Country [164] 0 0
Turkey
State/province [164] 0 0
Ankara
Country [165] 0 0
Turkey
State/province [165] 0 0
Antalya
Country [166] 0 0
Turkey
State/province [166] 0 0
Atakum
Country [167] 0 0
Turkey
State/province [167] 0 0
Denizli
Country [168] 0 0
Turkey
State/province [168] 0 0
Istanbul
Country [169] 0 0
United Kingdom
State/province [169] 0 0
Aberdeen
Country [170] 0 0
United Kingdom
State/province [170] 0 0
Birmingham
Country [171] 0 0
United Kingdom
State/province [171] 0 0
Colchester
Country [172] 0 0
United Kingdom
State/province [172] 0 0
Liverpool
Country [173] 0 0
United Kingdom
State/province [173] 0 0
London
Country [174] 0 0
United Kingdom
State/province [174] 0 0
Middlesborough
Country [175] 0 0
United Kingdom
State/province [175] 0 0
Norwich
Country [176] 0 0
United Kingdom
State/province [176] 0 0
Staffordshire

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Janssen Research & Development, LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Janssen Research & Development, LLC Clinical Trial
Address 0 0
Janssen Research & Development, LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Study Contact
Address 0 0
Country 0 0
Phone 0 0
844-434-4210
Fax 0 0
Email 0 0
Participate-In-This-Study@its.jnj.com
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
When will data be available (start and end dates)?
Available to whom?
Available for what types of analyses?
How or where can data be obtained?
IPD available at link: https://www.janssen.com/clinical-trials/transparency


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT05572515